Harmony Biosciences Holdings earnings release, May 7, 2026

Harmony Biosciences Holdings, Inc. (HRMY) · Form 8-K, Item 2.02 · Filed · SEC filing

HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES

​

WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion

​

Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent

​

Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications

​

Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026

​

Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timeframe

​

Expansion of the Leadership Team with the Addition of New COO and CFO to Support Scale and Next Phase of Growth

​

Conference Call and Webcast Today at 8:30 a.m. ET

​

PLYMOUTH MEETING, Pa., May 7, 2026 /Business Wire/

-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year

- over

- year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also outlined progress across four strategic priorities that it believes underpin long

- term shareholder value.

​

“Harmony is well positioned for long-term growth, and we are focused on four key pillars to drive value creation. First, protect the pitolisant franchise to ensure durability into the 2030s, supported by multi-layered intellectual property. Second, continued growth of the pitolisant franchise in an evolving market by advancing new formulations and differentiated approaches to solidify our leadership in the sleep/wake market. Third, drive value from our pipeline, led by BP-205, which has the potential to be a highly differentiated and best-in-class orexin-2 agonist across multiple indications. And fourth, a renewed emphasis on business development with a goal to transact on opportunities with revenue potential in the 2028–2032 timeframe,” said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. “Executing on these four pillars positions us well to deliver innovative treatments for patients and generate long-term value for shareholders.”

Key Pillars of Value Creation:

Protect the Pitolisant Franchise

​

​

Continued Pitolisant Franchise Growth in an Evolving Market

​

First Quarter 2026 Net Product Revenue for WAKIX

​

On track to achieve >$1 Billion in narcolepsy net sales in 2026

​

Pitolisant GR (gastro-resistant): On track to extend pitolisant franchise into the 2040s

​

Pitolisant HD (high dose): Opportunity to expand pitolisant franchise with differentiated labeling

​

Exploring novel amorphous form of pitolisant to pursue broader CNS indications

​

Drive Value from our Robust Pipeline

​

Orexin-2 receptor agonist BP-205 (BP1.15205)

​

EPX-100 (clemizole hydrochloride)

​

Renewed Emphasis on Business Development

​

​

Personnel Updates

​

First Quarter 2026 Financial Results

Harmony Biosciences reported net product revenue of $215.4 million for the quarter ended March 31, 2026, compared to $184.7 million for the same period in 2025, representing 17% year-over-year growth. This performance reflects both continued demand for WAKIX within the large narcolepsy market opportunity (approximately 80,000 diagnosed patients in the U.S.) and the product's broad clinical utility. The continued success has been driven by strong execution across the organization from sales effectiveness to marketing and promotion and supported by broad payer coverage and how the company supports patients over time.

​

Cost of product sold was $44.5 million in the first quarter of 2026, or 20.7% as a percentage of net product revenue, as compared to $32.0 million, or 17.3%, for the same quarter in 2025, representing a 39% increase. The increase in cost of product sold as a percentage of net product revenue was driven by new royalties related to the Novitium license agreement.

​

Net income for the quarter was $32.5 million, or $0.55 per diluted share, compared to $45.6 million, or $0.78 per diluted share, in Q1 2025. The decline in earnings was entirely driven by the licensing agreements entered into during Q1 2026.

​

Harmony’s operating expenses include the following:

​

As of March 31, 2026, Harmony had cash, cash equivalents and investments of $870.5 million, compared to $882.5 million as of December 31, 2025. The reduction was primarily due to up-front payments for license agreements and payment of ANDA settlements during Q1 2026.

​

2026 Net Product Revenue Guidance

Reiterated 2026 WAKIX Net Revenue Guidance of $1.0 Billion – $1.04 Billion

​

Conference Call Today at 8:30 a.m. ET

Harmony is hosting its first quarter 2026 financial results conference call and webcast today, beginning at 8:30 a.m. Eastern time. The live and replay webcast of the call will be available on the investor relations page of our website https://ir.harmonybiosciences.com/.

​

To participate in the live call by phone, dial: (

888) 596-4144 (domestic) or (646) 968-2525 (international, alternate); reference passcode

6626692

​

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities... (truncated)Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

​

Financial statements

Income Statement

Three Months Ended March 31, — (In thousands, except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net product revenue215,387184,733
Cost of product sold44,51231,994
Gross profit170,875152,739
Operating expenses:Research and development69,38334,540
Operating expenses:Sales and marketing31,69430,711
Operating expenses:General and administrative32,50731,243
Operating expenses:Total operating expenses133,58496,494
Operating expenses:Operating income37,29156,245
Operating expenses:Other (expense) income, net-127-276
Operating expenses:Interest expense-3,234-3,836
Operating expenses:Interest income5,7575,044
Operating expenses:Income before income taxes39,68757,177
Operating expenses:Income tax expense-7,199-11,617
Operating expenses:Net income32,48845,560
Operating expenses:Unrealized (loss) income on investments-759179
Operating expenses:Comprehensive income31,72945,739
EARNINGS PER SHARE:Basic0.560.79
EARNINGS PER SHARE:Diluted0.550.78
EARNINGS PER SHARE:Weighted average number of shares of common stock - basic57,819,06057,309,938
EARNINGS PER SHARE:Weighted average number of shares of common stock - diluted58,776,29758,524,566

Balance Sheet

December 31, — (In thousands, except share and per share data)

March 31, – 2026December 31, – 2025
CURRENT ASSETS:Cash and cash equivalents589,398752,502
CURRENT ASSETS:Investments, short-term51,52022,838
CURRENT ASSETS:Trade receivables, net108,22296,787
CURRENT ASSETS:Inventory, net5,2815,357
CURRENT ASSETS:Prepaid expenses16,80116,014
CURRENT ASSETS:Other current assets7,59513,516
CURRENT ASSETS:Total current assets778,817907,014
NONCURRENT ASSETS:Investments, long-term229,555107,127
NONCURRENT ASSETS:Intangible assets, net83,45789,418
NONCURRENT ASSETS:Deferred tax asset153,562149,699
NONCURRENT ASSETS:Other noncurrent assets26,43318,373
NONCURRENT ASSETS:Total noncurrent assets493,007364,617
NONCURRENT ASSETS:TOTAL ASSETS1,271,8241,271,631
CURRENT LIABILITIES:Trade payables28,60017,693
CURRENT LIABILITIES:Accrued compensation6,72618,443
CURRENT LIABILITIES:Accrued expenses150,107191,039
CURRENT LIABILITIES:Current portion of long-term debt20,00020,000
CURRENT LIABILITIES:Other current liabilities11,9074,957
CURRENT LIABILITIES:Total current liabilities217,340252,132
NONCURRENT LIABILITIES:Long-term debt, net138,814143,663
NONCURRENT LIABILITIES:Other noncurrent liabilities5,3215,618
NONCURRENT LIABILITIES:Total noncurrent liabilities144,135149,281
NONCURRENT LIABILITIES:TOTAL LIABILITIES361,475401,413
STOCKHOLDERS’ EQUITY:Common stock—$0.00001 par value; 500,000,000 shares authorized at March 31, 2026, and December 31, 2025, respectively; 57,867,389 and 57,726,170 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively11
STOCKHOLDERS’ EQUITY:Additional paid in capital717,370708,968
STOCKHOLDERS’ EQUITY:Accumulated other comprehensive (loss) income-413346
STOCKHOLDERS’ EQUITY:Retained earnings193,391160,903
STOCKHOLDERS’ EQUITY:TOTAL STOCKHOLDERS’ EQUITY910,349870,218
STOCKHOLDERS’ EQUITY:TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY1,271,8241,271,631
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; plans to submit an NDA for Pitolisant GR; plans to submit an IND for BP-205; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including EPX-100, Pitolisant GT and BP-205; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (“Bioprojet”); the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions, including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward- looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Harmony Biosciences Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.